Últimas noticias sobre CVRx (NASDAQ:CVRX) Bolsa

CVRX INC

CVRx

CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.

Levi Strauss

News

Pre-Market Outlook

Markets

Movers

AREB

BJDX

CHSN

CVRX

GLXG

GRFX

IPDN

IVDA

KNOP

KPTI

LEVI

PRSU

SOBR

STTK

SVRE

Levi sorprende al mercado con ganancias trimestrales mejores de lo esperado y una perspectiva 2025 que mantiene sin cambios.

Acciones de Levi Strauss suben un 10%; Aquí están 20 acciones que se mueven en el premercado de EE. UU.

CVRx Inc

<p><strong>CoreWeave Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWV#NASDAQ">CRWV</a>) just made a big move — but the market didn't applaud. Shares of <strong>Core Scientific Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORZ#NASDAQ">CORZ</a>) plunged nearly 21% on Monday, even as AI cloud provider CoreWeave announced it will acquire the <strong>Bitcoin</strong> (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) miner in <a href="https://www.benzinga.com/topic/bitcoin-miners">an all-stock deal</a>.</p>
<p>The twist? </p>
<p><strong>Beth Kindig</strong>, CEO and Lead Tech Analyst at I/O Fund, flagged the valuation in a post on X:</p>
<p><figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"><br />
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><p lang="en" dir="ltr">CoreWeave <a href="https://twitter.com/search?q=%24CRWV&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$CRWV</a> has agreed to acquire Core Scientific <a href="https://twitter.com/search?q=%24CORZ&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$CORZ</a> in an all-stock transaction expected to close in Q4.<br /><br />The exchange ratio implies a $9 billion equity valuation for <a href="https://twitter.com/search?q=%24CORZ&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$CORZ</a>, or $20.40 per share value.</p>
<p>&mdash; Beth Kindig (@Beth_Kindig) <a href="https://twitter.com/Beth_Kindig/status/1942202259799957952?ref_src=twsrc%5Etfw">July 7, 2025</a></p></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
<p></p></figure></p>
<p>The exchange ratio values Core Scientific at a jaw-dropping $9 billion — or $20.40 per share, a massive premium over its pre-deal price of under $11. That's a valuation level this Bitcoin mining company could have secured only during the heady crypto boom days of 2021. And markets aren't buying it.</p>
<p><strong>Read Also: <a href="https://www.benzinga.com/trading-ideas/movers/25/07/46280108/coreweave-core-scientific-shares-move-lower-on-9-billion-all-stock-deal">CoreWeave, Core Scientific Shares Move Lower On $9 Billion All-Stock Deal</a></strong></p>
<p>CoreWeave's stock also dipped 3.9% on the news, despite its own red-hot 293% year-to-date rally. While the company touts the acquisition as a strategic play to vertically integrate and secure cheap, scalable power for its AI infrastructure, investors seem skeptical of marrying high-growth AI with high-volatility crypto mining.</p>
<p>That's a head-turner in today's market, where Bitcoin miners have struggled with compressed margins, regulatory uncertainty, and post-halving revenue pressure. </p>
<p>Core Scientific is down 12% in the past month and still negative year-to-date — yet CoreWeave's offer implies nearly double the current share price.</p>
<p>CoreWeave's bullish bet hinges on AI's insatiable energy appetite. Owning a Bitcoin mining company such as Core Scientific, which operates massive power-dense data centers, could give CoreWeave better control over energy infrastructure. But the question remains: Can a 2021-style crypto valuation fly in a 2025 market?</p>
<p>For now, the answer from investors is a resounding, "not yet."</p>
<p><strong>Read Next: </strong></p>
<ul class="wp-block-list">
<li><strong><a href="https://www.benzinga.com/markets/tech/25/07/46273662/no-plan-b-teslas-musk-premium-is-on-thin-ice">No Plan B &#8211; Tesla&#8217;s Musk Premium Is On Thin Ice</a></strong></li>
</ul>
<p><em>Photo: PJ McDonnell via Shutterstock</em></p>



Analyst Color

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Long Ideas

Analyst Ratings

Tech

Trading Ideas

$BTC

Core Scientific, Inc. - Class A Common Stock

CORZ

CRWV

CoreWeave Just Valued Core Scientific Like It's 2021 Again

<p><i>Fred Lampropoulos will continue to serve as Chairman of Merit's Board of Directors</i></p>
<p><i>Merit announces preliminary unaudited revenue for the quarter ended June 30, 2025</i></p>


Management

MMSI

Merit Medical Names Martha Aronson As President And CEO

Contracts

OPXS

Optex Systems Receives $2.8M Purchase Order For Optical Sighting System

<p><strong>Cadence Design Systems, Inc.&nbsp;</strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNS#NASDAQ">CDNS</a>) shares are lower Monday. They have found resistance around $325 again.</p>
<p>But they may be on the <a href="https://www.benzinga.com/news/25/07/46256825/nvidia-crowdstrike-wolfspeed-cadence-design-systems-and-microsoft-why-these-5-stocks-are-on-investors-radars-today">verge of a breakout</a>. This is why our technical analysis team has made it our <a href="https://www.benzinga.com/topic/stock-of-the-day">Stock of the Day</a>.</p>
<p>In the stock market, certain price levels have more importance than others. As you can see on the chart below, the $325 level is one for Cadence.</p>
<p><figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="531" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07155945/one-1024x531.png" alt="" class="wp-image-975421" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07155945/one-1024x531.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07155945/one-300x156.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07155945/one-768x398.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07155945/one.png 1402w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure></p>
<p>In early 2024, the stock was trending higher. There weren't enough sell orders to fill all of the buy orders. Those who wished to buy had to continually increase their bid prices to attract sellers into the market. This forced the shares into an uptrend.</p>
<p>In March 2024, the uptrend ended around $325.</p>
<p>There were enough sell orders to fill all of the buy orders. The buyers didn't need to keep pushing the price higher.</p>
<p>But soon after hitting this resistance, the shares reversed and headed lower. When this happened, some people thought their decision to buy was a mistake.</p>
<p><strong>Read Also:</strong> <a href="https://www.benzinga.com/markets/equities/25/07/46271577/trumps-big-beautiful-bill-slashes-solar-incentives-cathie-woods-ark-says-nuclear-may-now-be-cheapest-option-oklo-smr-ltbr-and-other-stocks-in-focus"><strong>Trump&#8217;s Big Beautiful Bill Slashes Solar Incentives — Cathie Wood&#8217;s Ark Says Nuclear May Now Be Cheapest Option: OKLO, SMR, LTBR And Other Stocks In Focus</strong></a></p>
<p>They also decided to get out at breakeven if they could eventually do so.</p>
<p>So when Cadence returned to this level in June 2024, these regretful buyers placed sell orders. And there were so many of them that it created resistance again at the same level.</p>
<p>A similar dynamic occurred in December. Remorseful buyers who paid around $325 in June 2024 saw a chance to finally get out at breakeven, and they took it. Their selling put a top on the price once again.</p>
<p>Then, some of the people who had bought shares attempted to exit at breakeven after the price returned to this level in January.  And again, resistance formed.</p>
<p>Now Cadence has returned to this important level once more. The same thing could happen.</p>
<p>However, if the stock can break out above $325, it will indicate that the sellers are no longer present. They have either canceled or finished their orders.</p>
<p>With these sellers out of the way and this large amount of supply taken off of the market, those who wish to buy may start to push the price higher again.</p>
<p><strong>Read Next:</strong> </p>
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/07/46276421/broadcom-tesla-mag-7-switch-musk-trump-feud"><strong>Musk Chaos Could Oust Tesla From Mag 7, Making Way For Broadcom</strong></a></li>
</ul>
<p><em>Image: Shutterstock</em></p>



Technicals

CDNS

Stock Of The Day: Breakout Time For Cadence Design?

<p>Horizon, a company offering tailored investment and technology solutions to financial advisors, is introducing two new actively managed ETFs: <strong>Horizon Core Bond ETF </strong>(BATS:<a class="ticker" href="https://www.benzinga.com/stock/BNDY#BATS">BNDY</a>) and <strong>Horizon Flexible Income ETF </strong>(BATS:<a class="ticker" href="https://www.benzinga.com/stock/FLXN#BATS">FLXN</a>). This expansion continues the company&#8217;s growth in its fast-growing <a href="https://www.benzinga.com/etfs">ETF family.</a></p>
<p>Both are structured to assist advisors in producing a steady income while managing risk using options overlays, a strategy that is growing in popularity due to interest rate uncertainty and volatile credit markets.</p>
<p><strong>Also Read: <a href="https://www.benzinga.com/etfs/specialty-etfs/25/07/46277766/tesla-troubles-amplified-by-musks-party-politics-etfs-on-edge">Tesla Troubles Amplified By Musk&#8217;s Party Politics: ETFs On Edge</a></strong></p>
<p>BNDY focuses on investment-grade fixed-income instruments across a range of maturities like government and corporate bonds, and adds put spread overlays to enhance return potential and buffer volatility. The fund carries an expense ratio of 0.65%.</p>
<p>FLXN, on the other hand, ventures into the high-yield debt space, providing flexibility to adjust holdings based on market conditions, once more employing put spread overlays to cushion downside risk and maximize returns. The expense ratio for this fund is 0.80%.</p>
<p>The launch follows hot on the heels of three other ETF rollouts by Horizon just last week, <strong>Horizon Core Equity ETF</strong> (BATS:<a class="ticker" href="https://www.benzinga.com/stock/STOX#BATS">STOX</a>), <strong>Horizon Dividend Income ETF </strong>(BATS:<a class="ticker" href="https://www.benzinga.com/stock/DIVN#BATS">DIVN</a>), and <strong>Horizon Managed Risk ETF</strong> (BATS:<a class="ticker" href="https://www.benzinga.com/stock/SFTY#BATS">SFTY</a>), bringing the firm&#8217;s ETF lineup to seven.</p>
<p>As fixed-income investing evolves, Horizon&#8217;s latest ETFs represent another step in providing advisers with more nimble and risk-conscious solutions in an increasingly complex market environment.</p>
<p><strong>Read Next: </strong></p>
<ul class="wp-block-list">
<li><strong><a href="https://www.benzinga.com/etfs/specialty-etfs/25/07/46281860/elons-america-party-etf-a-what-if-fund-of-musk-linked-stocks-like-tesla-nvidia">Elon&#8217;s America Party ETF: A What-If Fund Of Musk-Linked Stocks Like Tesla, Nvidia</a></strong></li>
</ul>
<p><em>Photo: Shutterstock</em></p>


New ETFs

ETFs

BNDY

DIVN

FLXN

SFTY

STOX

Horizon Expands ETF Lineup With 2 Funds For Smarter Bond Income And Volatility Defense

Earnings

EDUC

Educational Development Q1 EPS $(0.13) Up From $(0.15) YoY, Sales $7.100M Down From $9.993M YoY

<p>Ascendis Pharma A/S (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) today announced two oral presentations at ENDO 2025, the annual meeting of the Endocrine Society being held July 12-15, 2025, in San Francisco. Dr. Aliya Khan will present new data from Week 156 of the Company's Phase 3 PaTHway Trial demonstrating the safety and efficacy of long-term treatment with TransCon&#xAE; PTH (palopegteriparatide) in adults with hypoparathyroidism – including maintenance of serum and urine biochemistries within normal levels and sustained improvement in renal function. Dr. Carlos Bacino will present additional safety and tolerability data from Week 52 of the Company's pivotal ApproaCH Trial of once-weekly TransCon&#xAE; CNP (navepegritide) in children with achondroplasia.</p>


ASND

Ascendis Pharma To Present New Data From Week 156 Of Phase 3 PaTHway Trial Demonstrating Safety And Efficacy Of Long-Term Treatment With TransCon PTH In Adults With Hypoparathyroidism, At ENDO 2025

<p><strong>Qualcomm Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>) shares are trading lower on Monday amid possible trade tensions. It was reported that the U.S. is planning to restrict shipments of AI chips to Malaysia and Thailand over China concerns.</p>
<p>According to the&nbsp;<a href="https://www.latimes.com/business/story/2025-07-05/u-s-plans-ai-chip-curbs-on-malaysia-thailand-over-china-concerns?utm_source=chatgpt.com">Los Angeles Times</a>, President <strong>Donald Trump</strong>'s administration is planning new export restrictions that would require U.S. companies to obtain licenses before sending advanced AI chips to Malaysia and Thailand. The goal is to prevent the indirect transfer of sensitive technology to China.</p>
<p>The updated rules, expected to be proposed as soon as August, target countries that have recently seen a rise in chip-related investment and activity.</p>
<p>The measures will likely include temporary exemptions, allowing shipments from U.S. and allied companies to continue for a limited time without a license. Additional exceptions are also being considered to reduce potential supply chain disruptions.</p>
<p>Officials are also expected to scale back a separate rule on AI chip exports that had faced pushback from U.S. allies and tech firms like Nvidia.</p>
<p>Current restrictions on exports to China and over 40 other countries will stay in effect to curb smuggling and closely monitor sensitive markets.</p>
<p><strong>QCOM Price Action</strong>: At publication on Monday, Qualcomm shares are trading 2.54% lower at $158.09, according to data from <a href="https://www.google.com/url?sa=t&amp;source=web&amp;rct=j&amp;opi=89978449&amp;url=https://www.benzinga.com/pro/&amp;ved=2ahUKEwiWjf6OuKuOAxXbAHkGHVuJE9IQFnoECA4QAQ&amp;usg=AOvVaw0xIsPvjIcIIsWev01-6zR2">Benzinga Pro</a>.</p>
<p><strong>Read Now:</strong><br />    • <strong><a href="https://www.benzinga.com/news/politics/25/07/46283137/trump-vs-bezos-how-big-beautiful-bill-may-wreck-20k-ev-dream">Trump Vs. Bezos: How &#8216;Big Beautiful Bill&#8217; May Wreck $20K EV Dream</a></strong></p>
<p><em>Image via Shutterstock</em></p>


Global

QCOM

Qualcomm Stock Is Trading Lower Monday: What's Going On?

<p><a href="https://register.epo.org/application?number=EP20832031">https://register.epo.org/application?number=EP20832031</a></p>


Biotech

General

MBRX

Moleculin Biotech Has Been Granted European Patent Number EP3990041 titled "METHOD OF RECONSTITUTING LIPOSOMAL ANNAMYCIN (FOR THE TREATMENT OF CANCER)

BFST

Business First Bancshares To Acquire Progressive Bancorp, Inc. And Progressive Bank; Expects To Issue ~3,050,490 Shares Of Common Stock To Progressive Shareholders

<p>Ratings for Allegro Microsystems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGM#NASDAQ">ALGM</a>) were provided by 10 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.</p>
<p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">6</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $29.0, a high estimate of $42.00, and a low estimate of $22.00. This current average has increased by 7.41% from the previous average price target of $27.00. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1751918503_0.png" alt="price target chart" /></p>
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
<p>A clear picture of Allegro Microsystems's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Timothy Arcuri</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$42.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Joseph Quatrochi</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$33.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Timothy Arcuri</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$35.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Vivek Arya</td>
<td>B of A Securities</td>
<td>Announces</td>
<td>Buy</td>
<td>$38.00</td>
<td>-</td>
</tr>
<tr>
<td>Joseph Moore</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$25.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Timothy Arcuri</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$25.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Blayne Curtis</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$23.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Quinn Bolton</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$25.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Timothy Arcuri</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$22.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Blayne Curtis</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$22.00</td>
<td>$30.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Allegro Microsystems. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Allegro Microsystems compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of Allegro Microsystems's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>For valuable insights into Allegro Microsystems's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/ALGM/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Allegro Microsystems analyst ratings.</strong></a></p>
<h2>Discovering Allegro Microsystems: A Closer Look</h2>
<p>Allegro Microsystems Inc is a designer, developer, fabless manufacturer, and marketer of sensor ICs and application-specific analog power ICs for automotive and industrial markets. Its Sensor IC allows customers to precisely measure motion, speed, position, and current, and Power ICs include high-temperature and high-voltage capable motor drivers, power management, and LED driver ICs. Its products are divided into three categories such as SENSE which includes Current Sensors, Switches and Latches, and Interface ICs among others; REGULATE which includes Regulators, ClearPower Modules, and LED Drivers; and DRIVE which includes BLDC Drivers, Brush DC, and others. Key revenue for the company is generated from Greater China and the rest from the United States, Japan, Europe, and other regions.</p>
<h3>A Deep Dive into Allegro Microsystems's Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Challenges:</strong> Allegro Microsystems's revenue growth over 3M faced difficulties. As of 31 March, 2025, the company experienced a decline of approximately <strong>-19.85%</strong>. This indicates a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Information Technology sector.</p>
<p><strong>Net Margin:</strong> Allegro Microsystems's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of <strong>-7.68%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Allegro Microsystems's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of <strong>-1.59%,</strong> the company may encounter challenges in delivering satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Allegro Microsystems's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of <strong>-1.03%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Debt Management:</strong> Allegro Microsystems's debt-to-equity ratio is notably higher than the industry average. With a ratio of <b>0.4</b>, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


ALGM

Breaking Down Allegro Microsystems: 10 Analysts Share Their Views

<p>In the last three months, 13 analysts have published ratings on Qualcomm (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>), offering a diverse range of perspectives from bullish to bearish.</p>
<p>The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">4</td>
<td align="right">3</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $176.38, a high estimate of $225.00, and a low estimate of $140.00. This current average represents a 11.03% decrease from the previous average price target of $198.25. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1751918487_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>The perception of Qualcomm by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Christopher Danely</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$170.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Tal Liani</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$200.00</td>
<td>$245.00</td>
</tr>
<tr>
<td>Mark Lipacis</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>In-Line</td>
<td>$157.00</td>
<td>$179.00</td>
</tr>
<tr>
<td>Gary Mobley</td>
<td>Loop Capital</td>
<td>Lowers</td>
<td>Hold</td>
<td>$155.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Matthew Prisco</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$150.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Aaron Rakers</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$140.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Christopher Rolland</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Positive</td>
<td>$190.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Tristan Gerra</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$216.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Kevin Cassidy</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Buy</td>
<td>$225.00</td>
<td>$225.00</td>
</tr>
<tr>
<td>Cody Acree</td>
<td>Benchmark</td>
<td>Lowers</td>
<td>Buy</td>
<td>$200.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>Samik Chatterjee</td>
<td>JP Morgan</td>
<td>Announces</td>
<td>Overweight</td>
<td>$185.00</td>
<td>-</td>
</tr>
<tr>
<td>Christopher Danely</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$145.00</td>
<td>$185.00</td>
</tr>
<tr>
<td>Joshua Buchalter</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Buy</td>
<td>$160.00</td>
<td>$195.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Qualcomm. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Qualcomm compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of Qualcomm's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Qualcomm's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/QCOM/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Qualcomm analyst ratings.</strong></a></p>
<h2>Get to Know Qualcomm Better</h2>
<p>Qualcomm develops and licenses wireless technology and designs chips for smartphones. The company's key patents revolve around CDMA and OFDMA technologies, which are standards in wireless communications that are the backbone of all 3G, 4G, and 5G networks. Qualcomm's IP is licensed by virtually all wireless device makers. The firm is also the world's largest wireless chip vendor, supplying nearly every premier handset maker with leading-edge processors. Qualcomm also sells RF-front end modules into smartphones, as well as chips into automotive and Internet of Things markets.</p>
<h3>Financial Insights: Qualcomm</h3>
<p><strong>Market Capitalization Analysis:</strong> Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Qualcomm's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>16.93%</strong> as of 31 March, 2025, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Information Technology sector.</p>
<p><strong>Net Margin:</strong> Qualcomm's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>25.61%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> Qualcomm's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>10.3%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>5.07%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> Qualcomm's debt-to-equity ratio stands notably higher than the industry average, reaching <strong>0.53</strong>. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Expectations For Qualcomm's Future

<p>Investors with a lot of money to spend have taken a bullish stance on <strong>HCA Healthcare</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with HCA, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 8 uncommon options trades for HCA Healthcare.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 37% bullish and 37%, bearish.</p>
<p>Out of all of the special options we uncovered, 4 are puts, for a total amount of $190,309, and 4 are calls, for a total amount of $216,902.</p>
<h3>Projected Price Targets</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $290.0 to $480.0 for HCA Healthcare over the recent three months. </p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>In today's trading context, the average open interest for options of HCA Healthcare stands at 95.57, with a total volume reaching 255.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in HCA Healthcare, situated within the strike price corridor from $290.0 to $480.0, throughout the last 30 days.</p>
<h3>HCA Healthcare 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1751918484_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th align="right"><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>HCA</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/18/26</td>
<td>$42.5</td>
<td>$39.1</td>
<td>$40.8</td>
<td>$390.00</td>
<td>$114.2K</td>
<td align="right">14</td>
<td align="right">0</td>
</tr>
<tr>
<td>HCA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/18/26</td>
<td>$21.5</td>
<td>$20.2</td>
<td>$21.5</td>
<td>$340.00</td>
<td>$73.1K</td>
<td align="right">0</td>
<td align="right">48</td>
</tr>
<tr>
<td>HCA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/18/26</td>
<td>$22.3</td>
<td>$20.5</td>
<td>$21.7</td>
<td>$440.00</td>
<td>$47.7K</td>
<td align="right">15</td>
<td align="right">22</td>
</tr>
<tr>
<td>HCA</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>03/20/26</td>
<td>$39.0</td>
<td>$36.4</td>
<td>$37.69</td>
<td>$390.00</td>
<td>$45.2K</td>
<td align="right">0</td>
<td align="right">24</td>
</tr>
<tr>
<td>HCA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/18/26</td>
<td>$9.4</td>
<td>$6.5</td>
<td>$9.4</td>
<td>$290.00</td>
<td>$45.1K</td>
<td align="right">3</td>
<td align="right">50</td>
</tr>
</tbody>
</table>
</p>
<h3>About HCA Healthcare</h3>
<p>HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the United States. As of December 2024, the firm owned and operated 190 hospitals, 124 freestanding outpatient surgery centers, and a broad network of physician offices, urgent-care clinics, and freestanding emergency rooms across 20 states and a small foothold in England.</p>
<p>In light of the recent options history for HCA Healthcare, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Where Is HCA Healthcare Standing Right Now?</h3>
<ul>
<li>With a volume of 881,219, the price of HCA is down -0.29% at $375.5. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 18 days.</li>
</ul>
<h3>What Analysts Are Saying About HCA Healthcare</h3>
<p>Over the past month, 2 industry analysts have shared their insights on this stock, proposing an average target price of $407.0.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Morgan Stanley persists with their Equal-Weight rating on HCA Healthcare, maintaining a target price of $410.<br />
&#x2A; Consistent in their evaluation, an analyst from RBC Capital keeps a Outperform rating on HCA Healthcare with a target price of $404. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for HCA Healthcare with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.</p>


Options

Behind the Scenes of HCA Healthcare's Latest Options Trends

<p>Investors with a lot of money to spend have taken a bullish stance on <strong>Cleanspark</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLSK#NASDAQ">CLSK</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with CLSK, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 21 uncommon options trades for Cleanspark.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 42% bullish and 38%, bearish.</p>
<p>Out of all of the special options we uncovered, 3 are puts, for a total amount of $449,950, and 18 are calls, for a total amount of $705,624.</p>
<h3>What's The Price Target?</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $8.0 to $20.0 for Cleanspark over the recent three months. </p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Cleanspark's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Cleanspark's substantial trades, within a strike price spectrum from $8.0 to $20.0 over the preceding 30 days.</p>
<h3>Cleanspark Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1751918479_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>CLSK</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$9.4</td>
<td>$9.35</td>
<td>$9.35</td>
<td>$20.00</td>
<td>$233.7K</td>
<td>1.3K</td>
<td>0</td>
</tr>
<tr>
<td>CLSK</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/25/25</td>
<td>$1.22</td>
<td>$1.2</td>
<td>$1.22</td>
<td>$12.00</td>
<td>$109.8K</td>
<td>2.0K</td>
<td>1.0K</td>
</tr>
<tr>
<td>CLSK</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/25/25</td>
<td>$1.1</td>
<td>$1.06</td>
<td>$1.06</td>
<td>$12.00</td>
<td>$106.4K</td>
<td>2.0K</td>
<td>2.0K</td>
</tr>
<tr>
<td>CLSK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$1.67</td>
<td>$1.65</td>
<td>$1.67</td>
<td>$15.00</td>
<td>$83.5K</td>
<td>24.2K</td>
<td>382</td>
</tr>
<tr>
<td>CLSK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$3.4</td>
<td>$3.25</td>
<td>$3.39</td>
<td>$10.00</td>
<td>$67.8K</td>
<td>17.5K</td>
<td>234</td>
</tr>
</tbody>
</table>
</p>
<h3>About Cleanspark</h3>
<p>Cleanspark Inc is a bitcoin mining company. Through CleanSpark, Inc., and the Company's wholly owned subsidiaries, the company mines bitcoin. The company entered the bitcoin mining industry through its acquisition of ATL. Bitcoin mining is the sole reportable segment of the company.</p>
<h3>Cleanspark's Current Market Status</h3>
<ul>
<li>With a volume of 29,651,627, the price of CLSK is down -2.12% at $11.99. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 31 days.</li>
</ul>
<h3>What The Experts Say On Cleanspark</h3>
<p>A total of 3 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $16.67.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; Maintaining their stance, an analyst from JP Morgan continues to hold a Overweight rating for Cleanspark, targeting a price of $14.<br />
&#x2A; An analyst from Chardan Capital has decided to maintain their Buy rating on Cleanspark, which currently sits at a price target of $20.<br />
&#x2A; An analyst from B. Riley Securities downgraded its action to Buy with a price target of $16. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Cleanspark, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.</p>


CLSK

Smart Money Is Betting Big In CLSK Options

<p>Deep-pocketed investors have adopted a bullish approach towards Fortinet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTNT#NASDAQ">FTNT</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in FTNT usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 14 extraordinary options activities for Fortinet. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 78% leaning bullish and 7% bearish. Among these notable options, 2 are puts, totaling $109,710, and 12 are calls, amounting to $810,389.</p>
<h3>Projected Price Targets</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $50.0 and $140.0 for Fortinet, spanning the last three months.</p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Fortinet's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Fortinet's whale trades within a strike price range from $50.0 to $140.0 in the last 30 days. </p>
<h3>Fortinet 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1751918473_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>FTNT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/19/25</td>
<td>$6.6</td>
<td>$6.2</td>
<td>$6.6</td>
<td>$120.00</td>
<td>$127.3K</td>
<td>694</td>
<td>0</td>
</tr>
<tr>
<td>FTNT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/20/26</td>
<td>$4.5</td>
<td>$4.05</td>
<td>$4.5</td>
<td>$140.00</td>
<td>$121.5K</td>
<td>89</td>
<td>270</td>
</tr>
<tr>
<td>FTNT</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$5.7</td>
<td>$5.55</td>
<td>$5.55</td>
<td>$105.00</td>
<td>$77.7K</td>
<td>638</td>
<td>167</td>
</tr>
<tr>
<td>FTNT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/11/25</td>
<td>$0.32</td>
<td>$0.17</td>
<td>$0.3</td>
<td>$111.00</td>
<td>$75.5K</td>
<td>1.2K</td>
<td>2.5K</td>
</tr>
<tr>
<td>FTNT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/11/25</td>
<td>$0.71</td>
<td>$0.52</td>
<td>$0.65</td>
<td>$109.00</td>
<td>$69.5K</td>
<td>645</td>
<td>1.2K</td>
</tr>
</tbody>
</table>
</p>
<h3>About Fortinet</h3>
<p>Fortinet is a platform-based cybersecurity vendor with product offerings covering network security, cloud security, zero-trust access, and security operations. The firm derives a majority of its revenue through sales of its subscriptions and support-based business. The California-based firm has more than 800,000 customers across the world.</p>
<p>After a thorough review of the options trading surrounding Fortinet, we move to examine the company in more detail. This includes an assessment of its current market status and performance.</p>
<h3>Current Position of Fortinet</h3>
<ul>
<li>Currently trading with a volume of 3,315,788, the FTNT's price is down by -0.1%, now at $105.55. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 30 days.</li>
</ul>
<h3>Expert Opinions on Fortinet</h3>
<p>1 market experts have recently issued ratings for this stock, with a consensus target price of $125.0.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; Maintaining their stance, an analyst from Rosenblatt continues to hold a Buy rating for Fortinet, targeting a price of $125. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Fortinet with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.</p>


FTNT

Unpacking the Latest Options Trading Trends in Fortinet

<p>In the last three months, 10 analysts have published ratings on Prudential Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRU#NYSE">PRU</a>), offering a diverse range of perspectives from bullish to bearish.</p>
<p>The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">10</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets, analyzed by analysts, offer insights with an average target of $112.9, a high estimate of $120.00, and a low estimate of $106.00. This current average represents a 4.0% decrease from the previous average price target of $117.60. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1751918472_0.png" alt="price target chart" /></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<p>The perception of Prudential Financial by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alex Scott</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$119.00</td>
<td>$109.00</td>
</tr>
<tr>
<td>Brian Meredith</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$110.00</td>
<td>$122.00</td>
</tr>
<tr>
<td>Nigel Dally</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$117.00</td>
<td>$108.00</td>
</tr>
<tr>
<td>Ryan Krueger</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$117.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Elyse Greenspan</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$113.00</td>
<td>$108.00</td>
</tr>
<tr>
<td>John Barnidge</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$109.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>John Barnidge</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$110.00</td>
<td>$122.00</td>
</tr>
<tr>
<td>Alex Scott</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$106.00</td>
<td>$134.00</td>
</tr>
<tr>
<td>Elyse Greenspan</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$108.00</td>
<td>$118.00</td>
</tr>
<tr>
<td>Ryan Krueger</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$120.00</td>
<td>$125.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Prudential Financial. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Prudential Financial compared to the broader market.</li>
<li><strong>Price Targets:</strong> Understanding forecasts, analysts offer estimates for Prudential Financial's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Prudential Financial's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/PRU/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Prudential Financial analyst ratings.</strong></a></p>
<h2>All You Need to Know About Prudential Financial</h2>
<p>Prudential Financial is a large, diversified insurance company offering annuities, life insurance, retirement plan services, and asset-management products. While it operates in a number of countries, the vast majority of revenue is generated in the United States and Japan. The company's investment management business, PGIM, contributes approximately 10% of its earnings and has around $1.3 trillion in assets under management. The US businesses are responsible for about 50% of earnings and can be classified into Institutional Retirement Strategies, Individual Retirement Strategies, Group Insurance, Individual Life Insurance, and Assurance IQ. Finally, the international business segment of the company contributes approximately 40% of earnings with a strong market position in Japan.</p>
<h3>Financial Milestones: Prudential Financial's Journey</h3>
<p><strong>Market Capitalization Analysis:</strong> Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.</p>
<p><strong>Decline in Revenue:</strong> Over the 3M period, Prudential Financial faced challenges, resulting in a decline of approximately <strong>-42.55%</strong> in revenue growth as of 31 March, 2025. This signifies a reduction in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Financials sector.</p>
<p><strong>Net Margin:</strong> Prudential Financial's net margin excels beyond industry benchmarks, reaching <strong>5.15%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> Prudential Financial's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of <strong>2.41%,</strong> the company may encounter challenges in delivering satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>0.09%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> With a high debt-to-equity ratio of <strong>0.75</strong>, Prudential Financial faces challenges in effectively managing its debt levels, indicating potential financial strain.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


A Glimpse Into The Expert Outlook On Prudential Financial Through 10 Analysts

<p>In the latest quarter, 4 analysts provided ratings for Sitio Royalties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STR#NYSE">STR</a>), showcasing a mix of bullish and bearish perspectives.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $22.75, a high estimate of $26.00, and a low estimate of $21.00. This current average represents a 4.21% decrease from the previous average price target of $23.75. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1751918464_0.png" alt="price target chart" /></p>
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
<p>A clear picture of Sitio Royalties's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Betty Jiang</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$22.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Mark Lear</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$26.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>William Janela</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$22.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Betty Jiang</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$21.00</td>
<td>$23.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Sitio Royalties. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Sitio Royalties compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts provide insights into price targets, offering estimates for the future value of Sitio Royalties's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Sitio Royalties's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/STR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Sitio Royalties analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.</p>
<h2>Get to Know Sitio Royalties Better</h2>
<p>Sitio Royalties Corp is a pure-play mineral and royalty company. The group focuses on investing in mineral and royalty interests in the Permian and other productive U.S. oil basins.</p>
<h3>Understanding the Numbers: Sitio Royalties's Finances</h3>
<p><strong>Market Capitalization Analysis:</strong> Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Sitio Royalties's revenue growth over a period of 3M has been noteworthy. As of 31 March, 2025, the company achieved a revenue growth rate of approximately <strong>8.01%</strong>. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Energy sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> Sitio Royalties's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of <strong>6.03%,</strong> the company may encounter challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Sitio Royalties's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>0.68%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Sitio Royalties's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of <strong>0.21%,</strong> the company may face hurdles in generating optimal returns from its assets.</p>
<p><strong>Debt Management:</strong> With a high debt-to-equity ratio of <strong>0.76</strong>, Sitio Royalties faces challenges in effectively managing its debt levels, indicating potential financial strain.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Breaking Down Sitio Royalties: 4 Analysts Share Their Views

<p><strong>Duolingo's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DUOL#NYSE">DUOL</a>) short percent of float has risen 29.02% since its last report. The company recently reported that it has <strong>1.85 million shares sold short</strong>, which is 5.29% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 2.35 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage"><strong>List of the most shorted stocks</strong></a></p>
<h3>Duolingo Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1751918462_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for Duolingo has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.</p>
<h3>Comparing Duolingo's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Duolingo's peer group average for short interest as a percentage of float is 4.17%, which means the company has <strong>more</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


Short Sellers

Short Ideas

DUOL

Looking Into Duolingo's Recent Short Interest

<p><strong>Grand Canyon Education's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOPE#NYSE">LOPE</a>) short percent of float has risen 22.67% since its last report. The company recently reported that it has <strong>399 thousand shares sold short</strong>, which is 1.84% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 1.8 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage"><strong>List of the most shorted stocks</strong></a></p>
<h3>Grand Canyon Education Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1751918457_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for Grand Canyon Education has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.</p>
<h3>Comparing Grand Canyon Education's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Grand Canyon Education's peer group average for short interest as a percentage of float is 4.32%, which means the company has <strong>less</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


LOPE

What's Driving the Market Sentiment Around Grand Canyon Education?

<p>During the last three months, 21 analysts shared their evaluations of Lam Research (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRCX#NASDAQ">LRCX</a>), revealing diverse outlooks from bullish to bearish.</p>
<p>The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">9</td>
<td align="right">7</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">7</td>
<td align="right">5</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $91.81, a high estimate of $115.00, and a low estimate of $70.00. Experiencing a 0.31% decline, the current average is now lower than the previous average price target of $92.10. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1751918454_0.png" alt="price target chart" /></p>
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
<p>The standing of Lam Research among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Atif Malik</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$108.00</td>
<td>$87.00</td>
</tr>
<tr>
<td>Joseph Moore</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$87.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Matthew Prisco</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Overweight</td>
<td>$115.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Craig Ellis</td>
<td>B. Riley Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$115.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Ed Yang</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$110.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Timothy Arcuri</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$95.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Harlan Sur</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$95.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Srini Pajjuri</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$90.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Melissa Weathers</td>
<td>Deutsche Bank</td>
<td>Lowers</td>
<td>Hold</td>
<td>$70.00</td>
<td>$78.00</td>
</tr>
<tr>
<td>Craig Ellis</td>
<td>B. Riley Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$95.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Charles Shi</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$80.00</td>
<td>$96.00</td>
</tr>
<tr>
<td>Joseph Moore</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$82.00</td>
<td>$81.00</td>
</tr>
<tr>
<td>Matthew Prisco</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Krish Sankar</td>
<td>TD Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$100.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Joseph Quatrochi</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$75.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Mark Lipacis</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$99.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Tom O'Malley</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$70.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Vivek Arya</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$90.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Brian Chin</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$92.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Timothy Arcuri</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$90.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Ed Yang</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$80.00</td>
<td>$95.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Lam Research. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Lam Research compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts provide insights into price targets, offering estimates for the future value of Lam Research's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Lam Research's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/LRCX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Lam Research analyst ratings.</strong></a></p>
<h2>About Lam Research</h2>
<p>Lam Research is one of the largest semiconductor wafer fabrication equipment manufacturers in the world. It specializes in deposition and etch, which entail the buildup of layers on a semiconductor and the subsequent selective removal of patterns from each layer. Lam holds the top market share in etch and holds the clear second share in deposition. It is more exposed to memory chipmakers for DRAM and NAND chips. It counts as top customers the largest chipmakers in the world, including TSMC, Samsung, Intel, and Micron.</p>
<h3>Lam Research's Financial Performance</h3>
<p><strong>Market Capitalization:</strong> Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.</p>
<p><strong>Revenue Growth:</strong> Lam Research displayed positive results in 3M. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately <strong>24.43%</strong>. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Information Technology sector.</p>
<p><strong>Net Margin:</strong> Lam Research's net margin is impressive, surpassing industry averages. With a net margin of <strong>28.19%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Lam Research's ROE excels beyond industry benchmarks, reaching <strong>14.53%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Lam Research's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>6.69%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of <strong>0.47</strong>, caution is advised due to increased financial risk.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


LRCX

The Analyst Verdict: Lam Research In The Eyes Of 21 Experts

Press Releases

CVRx to Present at the Piper Sandler 36th Annual Healthcare Conference

CVRx to Present at the 43rd Annual J.P. Morgan Healthcare Conference

CVRx Reports Preliminary Fourth Quarter and Fiscal Year 2024 Financial Results and Issues Fiscal 2025 Guidance

CVRx to Report Fourth Quarter 2024 Financial and Operating Results and Host Conference Call on February 4, 2025

CVRx Reports Fourth Quarter and Full Year 2024 Financial and Operating Results

CVRx announces new real-world evidence demonstrating significant reductions in healthcare utilization with Barostim

CVRx Reports Preliminary First Quarter 2025 Financial Results

CVRx to Report First Quarter 2025 Financial and Operating Results and Host Conference Call on May 8, 2025

Comments

CVRx

Noticias

Últimas noticias sobre CVRx (NASDAQ:CVRX) Bolsa

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL